跳至主要内容
临床试验/JPRN-UMIN000006649
JPRN-UMIN000006649招募中未知

Examination of efficacy and safety of PEG-IFN alpha-2a for the treatment of chronic hepatitis B. - PEG-IFN alpha-2a therapy for chronic hepatitis B.

Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine0 个研究点目标入组 100 人开始时间: 2012年1月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Patient who is administering the sho-sai-ko-to 2.A patient with the previous history of interstitial pneumonia 3.Other chronic liver disease patients such as autoimmune hepatitis or alcoholic hepatitis 4.Patient who has previous history of hypersensitivity for element of PEG-IFN alpha-2a or other IFNs 5.Patient who has previous history of hypersensitivity for biological products such as vaccines 6.Patient with cirrhosis, liver failure, and liver carcinoma 7.Hepatic encephalopathy, an esophageal varix, a patient with abdominal dropsy, or a patient with these previous history 8.A patient with autoimmune diseases (hemolytic anemia, chronic ulcerative colitis, rheumatoid arthritis, etc.), or a patient with these anamneses 9. Patient who has heart disease difficult to control (cardiac infarction, cardiac failure, and arrhythmia, etc.) 10. Patient who exists in serious state of mental disease of serious depression, thought of suicide or suicide plan, etc. or with these history 11. The patient of uncontrollable hypertension 12. A patient with the past of apoplexy (cerebral infarction, cerebral hemorrhage, subarachnoid bleeding, transient ischemic attack) 13. Pregnant woman or woman who has possibility of pregnancy or woman while suckling 14. Additionally, patient judged by doctor that participation in this study is improper

研究者

发起方
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine

相似试验